Furthermore, CLL cells were highly sensitive to the Akt inhibitor and more sensitive when obtained during ibrutinib treatment in vivo (P < 0.05; Figure 1F). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.